CompletedNot Applicable

Quality of Life 1y and 2 y After VV-ECMO for COVID-19

Belgium28 participantsStarted 2021-04-20

Plain-language summary

This study aims to investigate the quality of life and the outcome after veno-venous extracoporeal membrane oxygenation (ECMO) support fir severe acute respiratory syndrome (ARDS) in COVID-19 patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with PCR-confirmed COVID-19 infection AND * Acute Respiratory Distress Syndrome who require veno-venous ECMO therapy. Exclusion Criteria: * None

What they're measuring

in-hospital mortality

Timeframe: mortality during hospitalisation, up to two years

Quality of life 1y after ECMO insertion

Timeframe: 1 year

Quality of life 2y after ECMO insertion

Timeframe: 2 years

Trial details

NCT IDNCT05780255

SponsorUniversity Hospital, Ghent

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-01-31

View on ClinicalTrials.gov More COVID-19 Acute Respiratory Distress Syndrome trials